More people making choices
By 
This time in the boardrooms of international pharmaceutical companies (and one bank).
I’m going to flip the article and start with the corporations that aren’t helmed by collaborators.
Meanwhile, British drugmaker AstraZeneca and Denmark’s Novo Nordisk have recently said they remain committed to their DEI programs.
But over in Switzerland…
Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse panels for U.S. hiring, the latest companies acting to avoid penalties from recent U.S. executive orders.
No more will white Christian cishet males be subjected to the horrors of people who aren’t like them possibly having a say in whether they get that job which they absolutely do deserve.
Roche in particular is going along with the EOs = Laws now, and using it to take Republican discrimination worldwide.
Roche said the changes would also take effect outside the United States “because our global programmes and goals can have an impact on our U.S. organisations if we are not compliant under the new law”, according to the memo.
“Sorry, a misshapen orange bigot signed a paper.” Shrug emoji. But in German.
Among its measures, Roche said its Chief Diversity Offices in the U.S. and at its Basel headquarters “will focus on inclusion and belonging, and responsibilities will be re-scoped accordingly”. Diversity was not mentioned under the offices’ new remit.
[…]
Novartis told Reuters on Wednesday that evolving laws and policies in the U.S. would require it to change, and listed the end of its use of diverse panels as one immediate change to its own policies. The company continues to believe in “embracing varied perspectives and fostering equal opportunity for all of our people”, it added.
Until he tells them to knock that off too.
